[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 30 days · First seen · Last updated

Global pharmaceutical market trends

Overview

The provided data outlines growth projections and regulatory developments across different therapeutic sectors.

In the non-small cell lung cancer (NSCLC) market, PD-1 therapies are projected to grow from $27.5 billion in 2025 to $41.45 billion by 2030. This expansion is attributed to advancements in personalized medicine, genomic profiling, and the development of combination regimens involving chemotherapy or mRNA vaccines. Notable industry activity includes Akeso Inc. reporting positive Phase III results for ivonescimab and BioNTech SE acquiring Biotheus Inc. to access bispecific antibodies.

Separately, the Parkinson’s disease market is expected to reach $7.2 billion by 2033, up from $3.3 billion in 2023. Growth is driven by an aging population and new regulatory milestones, such as the FDA approval of AbbVie’s Juvmo and the European EMA approvals for NeuroDerm’s Onerji and Amneal’s Crexont/Hopledo. However, the market faces potential challenges from the loss of exclusivity for branded products and the subsequent entry of generics.

Entities

GlobalData · AbbVie · Amneal · The Business Research Company · Supernus

Timeline

  1. [HEALTH] 2 sources
    Parkinson’s disease market projected to reach $7.2 billion by 2033

    The Parkinson’s disease market in seven major regions is forecast to reach $7.2 billion by 2033, driven by new drug approvals and disease-modifying therapies.

  2. [BUSINESS] 2 sources
    PD-1 non-small cell lung cancer market to reach $41.45 billion by 2030

    The PD-1 non-small cell lung cancer market is projected to reach $41.45 billion by 2030, fueled by personalized medicine, combination therapies, and significant clinical advancements.

Sources

globaldata.com · healthcareasiamagazine.com · the-miyanichi.co.jp · youthsoccercup.com